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Abstract: Age-related macular degeneration (AMD) is the main cause of loss of sight in 
the world and is characterized by neovascularization of the macula. The factors producing 
choroidal vascularization involve various growth factors, including the vascular endothelial 
growth factor (VEGF165). In this context, the systematic evolution of ligands by exponential 
enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. 
The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in 
which DNA or RNA molecules (aptamers) are identiﬁ  ed by their ability to bind their targets 
with high afﬁ  nity and speciﬁ  city. Recently, the use of the SELEX technique was extended to 
isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, 
Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds 
to VEGF165 and inhibits angiogenesis, was approved by the Food and Drug Administration for 
the treatment of wet AMD, thereby providing signiﬁ  cant beneﬁ  ts to a great number of patients 
with minimal adverse effects.
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Introduction
Molecular sources are becoming gradually more important in the search for compounds 
that can potentially act as biological agents for in vivo and in vitro studies and possible 
drug candidates. According to the increasing amount of new therapeutic targets 
provided by genome and on-going proteome, the design of speciﬁ  c inhibitors of 
proteins associated with disease is one of the primary objectives in pharmacological 
research using the suitability of combinatorial libraries, which assumes that one 
member of a huge population of different molecules and structures, such as polyamines, 
carbohydrates, peptides and oligonucleotides, can ﬁ  t as ligand or inhibitor and modulate 
target protein activity (Janda 1994; Gold 1995; Ulrich 2006).
The Systematic Evolution of Ligands by EXponential enrichment (SELEX) 
technique which was introduced in parallel by Gold (Tuerk and Gold 1990) and 
Szostak (Ellington and Szostak 1990), uses an oligonucleotide-based combinatorial 
library containing a vast number of different sequences and structural motifs (about 
1014) for the in vitro selection of DNA or RNA molecules with binding speciﬁ  city to a 
desired target. These high-afﬁ  nity oligonucleotide-target binders are also denominated 
aptamers. Aptamers can interact with a variety of other selection targets including 
nucleotides (Sassanfar and Szostak 1993; Meli et al 2002), biologically active peptides, 
soluble proteins (Jellinek et al 1993; Williams et al 1996; Proske et al 2002), complex 
targets such as membrane receptors, blood vessels, erythrocyte surfaces (Ulrich et al 
1998; Blank et al 2001; Morris et al 2001) and entire cells (Homann and Göringer 
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Based on these features, aptamers became ideal candi-
dates for investigation of protein interactions in vitro, in 
animal models and also for developing novel lead compounds 
for pharmaceutical applications. These features are due to 
the unique capacity of aptamers to fold into tridimensional 
structures folding of aptamers based on their nucleic acid 
sequence. In many cases, aptamers bind with low dissocia-
tion constants to their targets in the nanomolar or picomolar 
range, resulting in larger binding afﬁ  nities than most of 
natural ligands or inhibitors used as competitors during the 
development of the aptamer (Ulrich et al 1998). Moreover, 
aptamers can interact with functional domains of a protein, 
most of all due to their smaller size compared to other ligands 
such as antibodies or other natural ligands, enabling aptamers 
to easily access their binding sites (Ulrich 2006).
In order to promptly achieve most of the designed prop-
erties, several kinds of modiﬁ  cations can be introduced to 
add speciﬁ  c characteristics to the aptamer such as nuclease 
resistance and enhancement of stability for in vivo appli-
cations. These characteristics can be obtained by adding 
phosphorothioate-based nucleotides to DNA aptamers or 
2′-ﬂ  uoro or 2′-amino-substitution of 2′OH groups of riboses 
of RNA aptamers (Pestourie et al 2005; Ulrich et al 2006). 
For improvement of pharmacokinetics and bioavailability 
high molecular weight or lipophilic moieties are attached 
to the 5′- or 3′- end of the aptamers. For instance, coupling 
an aptamer to a polyethylene glycol moiety increases half-
lives in plasma to about 9 hours instead of the few minutes 
observed with unmodiﬁ  ed aptamers (Willis et al 1998).
Another benefit of aptamers in in vivo experiments 
or therapeutic applications is the fact that they show low 
or no immunogenic responses. The proven non-toxicity of 
these molecules in preclinical and clinical trials, so far, makes 
aptamers promising candidates for therapeutic use (Eyetech 
Study Group 2002; Eyetech Study Group 2003). However, 
serious limitations for some applications of aptamers as 
diagnostic and/or pharmaceutical drugs are based on their 
incapacity to passively cross biological membranes, forcing 
most of researchers in industry to focus on extracellular-acting 
aptamers (reviewed in Rimmele 2003).
Even though being appropriate for an extensive range 
of different applications, a valid standardized protocol for 
aptamer selection for any given target molecule does not 
exist, as selection of aptamers signiﬁ  cantly depends on the 
properties of a target and its availability in sufﬁ  cient amount. 
In countless cases, the accomplishment of aptamer identiﬁ  ca-
tion with desired properties basically depended on the use 
of the precise conditions during in vitro selection, in which 
aptamers later exert their function (Jayasena 1999), such 
as correct concentrations of cations for accurate aptamer 
folding into secondary and tertiary structures. Additionally, 
negatively charged target molecules may turn into a problem 
for DNA and RNA aptamer selection, making it necessary to 
take these facts into account for the choice of target epitopes 
and solution conditions used during the SELEX process 
(Rimmele 2003).
SELEX: the process
The in vitro selection of RNA and DNA aptamers against 
speciﬁ  c targets obeys the same rules as natural selection does. 
Individual steps of aptamer selection are illustrated in Figure 1 
(Ulrich et al 2005). This selection of aptamers consists on the 
use of a library formed by two constants regions ﬂ  anking a 
middle random segment, which can vary from 20 to 75 random-
incorporated oligonucleotides. Constant regions should advis-
ably contain restriction enzyme sites to facilitate the insertion of 
the random regions of selected aptamers into a bacterial vector 
for sequencing. In addition, a T7-promoter site needs to be 
included in one of the constant regions in case RNA aptamers 
shall be selected. For the selection of RNA aptamers the original 
DNA pool is in vitro transcribed to RNA in the presence of 
modiﬁ  ed nucleotides and T7-RNA polymerase.
Re-iterative in vitro selection rounds initiate by present-
ing the target in standardized concentrations to the pool 
and separating target-bound molecules from the unbound 
molecules using several techniques including nitrocellulose 
ﬁ  lter adsorption (Ulrich et al 1998), afﬁ  nity chromatography 
(Trujillo et al 2007), gel-shift separation (Ulrich et al 1998; 
Tang and Shafer 2006) and magnetic beads (Bruno 1997). 
Selected RNA molecules are eluted from their target epitope, 
collected and reverse-transcribed to DNA to be ampliﬁ  ed 
by polymerase chain reaction (PCR). The ampliﬁ  ed DNA 
pool is again in vitro transcribed to RNA to originate the 
second SELEX cycle. As a general statement, the selec-
tion stringency in SELEX protocols is usually increased 
to ensure that only the strongest binders are selected. The 
originally heterogeneous RNA pool is puriﬁ  ed to a homoge-
neous population of high-afﬁ  nity target binders to the aimed 
target. This ﬁ  nal RNA pool is reverse transcribed to cDNA, 
PCR-ampliﬁ  ed and used for cloning and DNA sequencing. 
Consensus motifs located in the previous random sequences 
are searched within the aptamer clones in order to identify 
aptamers families with similar sequences and three-dimen-
sional structure. These conserved sequences are often located 
in stem-loops mediating aptamer-binding speciﬁ  city (Ulrich 
et al 2005). Based on observations that these stem-loops by Clinical Ophthalmology 2007:1(4) 395
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themselves may be sufﬁ  cient for binding speciﬁ  city and bio-
logical activity, aptamers may be truncated to these minimal 
sequences. As further post-SELEX processes, aptamers can 
be optimized for in vivo applications by introducing spe-
ciﬁ  c chemical modiﬁ  cations or attaching reporter groups or 
hydrophobic linkers to their extremities (reviewed by Ulrich 
et al 2006).
Age-related macular degeneration
Age-related macular degeneration (AMD) is the most com-
mon irreversible cause of vision loss and blindness in the 
elderly (Klein et al 2004; Michell and Bradley 2006). AMD 
is deﬁ  ned as the loss of macular function from the degenera-
tive changes of aging by the disruption of the interactions 
of the retinal pigment epithelium with the neural retina and 
the underlying choroidal vasculature (reviewed by Rowe-
Rendleman and Glickman 2004; Tezel et al 2004).
There are two described forms of AMD: dry (non-
exudative) and wet (exudative) (Nowak 2006). The 
dry AMD represents the form suffered from by more 
than 80% of the AMD patients and is characterized by 
the cumulative damage or genetic defects in the retinal 
pigment epithelium that causes or permits gradual cell 
loss (Bylsma and Guymer 2005). The wet AMD is 
described by neovascularization occurring either beneath 
the retinal pigment epithelium or between the epithelium 
and the retina, which can result in bleeding or exuding 
of ﬂ  uids (Heier 2006). This form of the degeneration is 
responsible for about only 10%–20% of the total cases of 
AMD. However, wet AMD causes 90% of cases of severe 
vision loss in patients with AMD (Berdeaux et al 2005). Its 
pathogenesis is not well known, although several metabolic, 
genetic and behavioral risk factors were described for AMD 
establishment (Churchill et al 2006; Schaumbeg et al 2007; 
De Angelis et al 2007). For instance, increased plasma 
levels of MMP-9 metalloprotease (Chau et al 2007), genetic 
susceptibility (Rivera et al 2005) and behavioral habit of 
smoking contribute to AMD formation.
Figure 1 In vitro selection of RNA aptamers by using the SELEX (Systematic Evolution of Ligand by EXponential enrichment) technique.   A chemically synthesized DNA 
pool is ampliﬁ  ed by polymerase chain reaction (PCR) in the presence of speciﬁ  c primers followed by in vitro transcription to the combinatorial RNA library contain-
ing 1012–1014 different sequences. The presence of 2′F- or 2′-NH2-modiﬁ  ed pyrimidines instead of 2′OH-pyrimidines during the in vitro transcription reaction provides 
nuclease-resistance to the synthesized RNA pool. Secondary structure formation of these RNA molecules is induced by thermal de- and re-naturation. Then the RNA pool 
containing diverse structural motifs is presented to its selection target (ie, VEGF), followed by collection of target bound RNA molecules which are reverse-transcribed to 
cDNA followed by PCR reaction. The RNA pool used for the second SELEX cycle is again obtained by in vitro transcription. Reiterative SELEX rounds are performed until 
the diversity of the original combinatorial RNA pool has been narrowed down to a homogeneous population of high-afﬁ  nity target binders. This ﬁ  nal RNA pool is reverse-
transcribed to cDNA, ampliﬁ  ed by PCR and sequenced for aptamer identiﬁ  cation. Using post-SELEX modiﬁ  cations, identiﬁ  ed aptamers are optimized for in vivo applications 
regarding nuclease resistance, thermal stability and pharmacokinetics.Clinical Ophthalmology 2007:1(4) 396
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The factors initiating and maintaining disease-causing 
neovascularization in AMD are yet to be identiﬁ  ed. However, 
it is now generally accepted that growth factors, mainly the 
vascular endothelial growth factor (VEGF), signiﬁ  cantly con-
tribute to this process. The VEGF gene family is divided into 
seven members; snake venom (VEGF-F), VEGF-E, placenta 
growth factor (PIGF), VEGF-C, VEGF-B, and VEGF-A, 
which bind with different afﬁ  nities and speciﬁ  cities to three 
types of tyrosine kinase receptors (VEGFR1, VEGFR2 and 
VEGFR3) (Fournier et al 1997).
VEGF-A, a 35–45 kDa homodimeric protein, triggers phar-
macological responses after binding to VEGFR1 and VEGFR2 
and is also implicated in angiogenesis and neovascular diseases 
such as AMD and diabetic macular edema, a thickening of the 
retina occurring as a result of an abnormal accumulation of 
ﬂ  uid within the retina (Ng et al 2006). VEGF-A has at least six 
different isoforms as a result of alternative splicing of a com-
mon mRNA. In humans, these are named VEGF121, VEGF145, 
VEGF165, VEGF165B, VEGF189, and VEGF206 (Bates et al 2002; 
Gustafsson et al 2005). VEGF165 is the most predominant 
isoform in the eye and is the target of Pegaptanib for AMD 
treatment (Figure 2) (McMahon 2000; Giles 2001).
From the RNA library 
to the pegaptanib
The development of Pegaptanib began in 1994 in order to 
increase the limited number of available speciﬁ  c ligands for 
VEGF165 for in vitro use (Figure 3). These few ligands were 
represented by a soluble truncated VEGF receptor aimed 
at the capture of circulating VEGF (Kendall and Thomas 
1993) and a monoclonal antibody that inhibited the growth 
of injected tumor cells in nude mice, but had no effect on the 
growth rate of tumor cells in vitro (Kim et al 1993).
Jellinek et al (1994) used an oligonucleotide-based 
combinatorial library composed by 30 contiguous 
randomized positions, ﬂ  anked by two constant regions for the 
in vitro selection of RNA molecules binding to VEGF165. The 
combinatorial RNA library used in the ﬁ  rst selection bound 
to VEGF with micromolar binding afﬁ  nity and following 13 
SELEX rounds, the afﬁ  nity of the RNA pool to its selection 
target improved a hundred times. From this ﬁ  nal selected 
RNA library, 64 sequences were identiﬁ  ed that generated 
37 consensus regions classiﬁ  ed in six structural families. 
The members of each family had conserved sequences and 
thus shared a deﬁ  ned secondary conformation in which 
conserved residues were organized in a singular motif with 
a respective functional property giving origin to many points 
of interaction with its target.
Candidates of all six families were screened in 
nitrocellulose ﬁ  lter binding assays showing their capability 
to compete with VEGF binding to its receptor; in addition, all 
RNA ligands competed for the heparin-binding site. Jellinek 
et al (1993) suggested that many proteins have principal 
sites for RNA or DNA binding, corroborating the idea of the 
existence of a common binding site of heparin and VEGF 
for all aptamers. Using the same binding assay, Jellinek 
and co-workers used these aptamers to identify two classes 
of VEGF receptors on human umbilical vein endothelial 
cells (HUVEC) with different dissociation constants to their 
ligands. However most interestingly, high-afﬁ  nity aptamers, 
denominated as sequences 100, 44, 12, 40, 84 and 126 (family 
1–6 respectively) blocked the interaction of VEGF165 with 
its receptor on the cell surface in a dose-dependent manner 
with dissociation constant in the range of 20–40 nM (Jellinek 
et al 1994). These observations showed that SELEX was an 
important tool for the discovery of speciﬁ  c inhibitors for 
VEGF165-induced biological activity for in vitro applications 
and initiated the development of an anti-VEGF aptamer for 
in vivo applications.
The next important step for an anti-VEGF therapeutic 
aptamer was achieved by Green et al (1995) by introducing 
chemical modiﬁ  cations granting RNA molecules nuclease 
resistance and improving their efﬁ  cacies for use in biological 
systems (for review see Ulrich et al 2006). The sensibility of 
RNA is based on 2′-OH groups of riboses which are used by 
nucleases for cleavage of the adjacent phosphodiester bound 
(Pieken et al 1991; Cummins et al 1995). For the SELEX pro-
cedure, Green et al (1995) incorporated 2′-aminopyrimidines 
into transcripts by enzymatic synthesis from two random 
libraries containing 1014 different RNA molecules. After 11 
reiterative SELEX rounds, afﬁ  nity of the evolved RNA pool  
increased a hundred times (dissociation constant ranged from 
pM to nM), and 79 unique sequences were isolated from the 
two libraries.
The consensus sequence of 24 conserved nucleotides in 
the previously randomized region was determined for the 
highest afﬁ  nity RNA ligand, named as NX-107 (Green et al 
1995). This aptamer with already improved resistance to deg-
radation by nucleases was further modiﬁ  ed for increased sta-
bilization and optimization towards therapy by O-methylation 
(2′-OMe) of 2′-OH groups of adenosine in position 12.
Furthermore, poly dT caps with phosphorothioate link-
ages to the 5′- and 3′-terminals were added without any effect 
aptamer afﬁ  nity to VEGF165. Further aptamer modiﬁ  cations 
were tested in order to identify the most effective one: NX-213 
was a capped aptamer with 2′-OMe purine modiﬁ  cation and Clinical Ophthalmology 2007:1(4) 397
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NX-178 a capped aptamer without purine modiﬁ  cations. 
The NX-223 aptamer had an inverted substitution pattern 
in its nucleotides. Purines of NX-224 were substituted by 
2′-OMe-purines, and the NX-191 aptamer was synthesized 
with 2′-OMe-modiﬁ  cations in all nucleotides. NX-178 and 
NX-213 with dissociation constants for VEGF binding as 
low as 0.1 nM, were in the following further characterized 
for their interaction with heparin-binding proteins and the 
thermal stabilities of the aptamer′s minimal sequence. As a 
result, a high afﬁ  nity RNA ligand resistant against degrada-
tion was obtained and the 2′-OMe post-SELEX modiﬁ  cation 
in NX-213 signiﬁ  cantly improved its half-life in rat urine 
sufﬁ  ciently to be a model for the next generation of aptamers 
as a therapeutic agent in clinical trials (Green et al 1995).
RNA aptamers were selected from a 2′-ﬂ  uoro-pyrimidine 
RNA library by Ruckman et al (1998) for further improvement 
of binding-affinity. 2′-F-pyrimidines are accepted as 
substrates by T7 RNA polymerase, and this modified 
oligonucleotide library does not destabilize the duplex 
conformation of RNA or DNA at physiological pH values in 
contrast to the 2′-aminopyrimidine substitution, resulting in a 
greater thermal stability and rigid conformation of secondary 
structures (Aurup et al 1994; Cummins et al 1995), which 
is theoretically followed by an increase in afﬁ  nity (Eaton 
et al 1995). In addition, Healy et al 2004 veriﬁ  ed that this 
type of modiﬁ  cation may improve aptamer tissue residence 
and plasma half-life. For instance, an aptamer containing 
2′-ﬂ  uoro-pyrimidine and 2′-O-methylpurine modiﬁ  cations 
remained signiﬁ  cantly longer in the circulation than did a 
completely 2′-O-methylated composition.
The aptamers against VEGF165 were prepared by Ruck-
man et al (Ruckman et al 1998) using 2′-ﬂ  uoro modiﬁ  ca-
tions RNA libraries containing 30 or 40 random nucleotides 
selected in 10 reiterative rounds. In comparison to the initial 
pool, the afﬁ  nity of the isolated 46 high-afﬁ  nity RNA to 
VEGF165 increased 1000-fold, resulting in dissociation 
Figure 2  VEGF receptor-induced signaling pathway.   VEGF plays a key role in physiological blood vessel formation and pathological angiogenesis such as tumor growth and 
ischemic diseases. VEGF-dependent cell survival is mediated via phosphatidyl inositol-3-kinase (PI3K)-induced activation of the anti-apoptotic kinase Akt, which inhibits the 
protein Bad, leading to inhibition of caspase activity and also causes Ca2+-independent activation of nitric oxide synthetase (NOS) through phosphorylation. This pathway is 
necessary for cellular migration.   A major mitogenic signaling mechanism for VEGF involves activation of  phospholipase C (PLC-γ) resulting in hydrolysis of phosphatidylino-
sitol 4,5-bisphosphate, production of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), and subsequent mobilization of intracellular Ca2+ and protein kinase C 
(PKC) activation. PKC mediates activation of extracellular signal regulated kinases (ERK) 1/2 via RAS, Raf-1 and MEK, mediating mitogenesis in association with mitogen-
activated protein kinases (MAPK). Binding of the growth factor to its corresponding cell surface receptor (VEGFR) activates complex signal transduction pathways, involving 
changes in protein phosphorylation, ion ﬂ  uxes, gene expression, protein synthesis and ultimately a biological response related with angiogenesis. Functional signaling 
converges at several points, emphasizing how signaling pathways are integrated to form signal transduction networks. For inhibition of this signaling pathway, the Pegaptanib 
binds to VEGF, blocking the formation of the complex VEGF-receptor and consequently inhibiting signal transduction and angiogenesis.
Abbreviation: ER, endoplasmic reticulum.Clinical Ophthalmology 2007:1(4) 398
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constants in the 5–50 pM range (Ruckman et al 1998). The 
evolved RNA aptamers could be grouped in three structural 
families based on conserved sequence motifs. For each of the 
aptamer families, minimal sequences sufﬁ  cient for binding 
activity were determined. The respective truncated aptamers 
containing 23–29 nucleotides, denominated as t22.29, t2.31 
and t44.29 were selected for 2′-OMe post-SELEX modiﬁ  ca-
tions in order to further enhance their nuclease resistance in 
biological ﬂ  uids (Beigelman et al 1995).
The 2′-O-methylated truncated aptamers (t22-OMe, 
t2-OMe and t44-OMe) were tested in terms of the divalent 
cation dependence and thermal stability, the speciﬁ  city 
for VEGF165 and inhibition of VEGF165–induced receptor 
activation in vivo by using the Miles assay (Miles and Miles 
1952; Senger et al 1986). With this assay, Ruckman et al 
(1998) could monitor the effect of aptamers on VEGF-
induced increase of leakage of microvessel in guinea pigs. 
Preincubation with 1 or 0.1 μM of VEGF with the mentioned 
aptamers (t22-OMe, t2-OMe and t44-OMe) and co-injection 
both demonstrated that the t44-OMe inhibited the vascular 
permeability by 58% or 48%, depending on the used VEGF 
concentrations. Furthermore, improving pharmacokinetics 
by conjugating the t44-OMe aptamer with a 40 kDa 
PEG polymer, preventing rapid VEGF elimination from 
plasma and prolonged systemic exposure facilitating tissue 
distribution of aptamers (Healy et al 2004), even increased 
aptamer potency in inhibiting VEGF activity (83% at 0.1 
μM of VEGF), although at the same time aptamer binding 
affinity to VEGF was reduced. Pharmacokinetics and 
biodistribution of the t44-OMe polyethylene glycol aptamer 
containing a VEGF165-binding sequence of 27 nucleotides 
plus an additional 3′-terminal deoxythymidine (pegaptanib), 
now renamed, NX1838 (Tucker et al 1999; Bell et al 
1999), were determined in rhesus monkeys. An intravenous 
administration of Pegaptanib resulted in aptamer half-life 
of approximately 9 h in circulation whereas unmodiﬁ  ed 
Figure 3 Timeline of the Pegaptanib development towards clinical trials for FDA approval. The ﬁ  rst aptamer ligand of VEGF was identiﬁ  ed by Jellinek et al (1994) from an 
unmodiﬁ  ed combinatorial RNA library, introducing the idea that a VEGF-binding aptamer could inhibit VEGF-receptor binding. In this work, evolved aptamers were classi-
ﬁ  ed in six structural families and one candidate of each family (100t, 44t, 12t, 40t, 84t and 126t) was analyzed in terms of afﬁ  nity. Observed dissociation constants (Kd) of 
aptamer-receptor binding were 20–40 nM. The CTP represents the chemical structure of nucleotides for wild type aptamers. Green et al (1995) selected aptamers from 
two RNA libraries carrying 2′-NH2 pyrimidine modiﬁ  cations and introduced 2′-OMe purine modiﬁ  cations (exempliﬁ  ed in the ﬁ  gure by 2′-NH2-dCTP and 2′-O-Methyl-dATP 
chemical structures, respectively) in already identiﬁ  ed aptamers leading to increased nuclease resistance and to improved in vivo stability and tissue distribution. Follow-
ing several experiments in order to determine the best modiﬁ  cations, Green et al (1995) had developed three aptamers named as NX-107, NX-178 and NX-213 with 
dissociation constants of 0.1 nM. Ruckman et al (1998) repeated the in vitro selection of VEGF-binding aptamers.   Three modiﬁ  ed aptamers with 2′-ﬂ  uoro pyrimidine and 
2′-OMe purine substitutions except for the adenines involved in VEGF165 binding  (exempliﬁ  ed in the ﬁ  gure by the 2′-F-dCTP and 2′- O-Methyl-dATP chemical structure, 
respectively)  were identiﬁ  ed. One of these aptamers was further developed into therapeutics. Following PEGylation T44-OMe was denominated as Pegaptanib. Other 
names were introduced by Bell et al (1999) (NX1838) and by Eyetech (EYE001) prior to its FDA approval in December, 2004 for therapeutic use in humans.Clinical Ophthalmology 2007:1(4) 399
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aptamers were eliminated within minutes (Willis et al 1998) 
at a clearance rate of 6 ml/h. Subcutaneous administration 
resulted in almost 80% absorption of aptamers into the 
plasma compartment, reaching peak concentrations after 
8 h (Tucker et al 1999).
Preclinical and clinical studies with NX1838 (now 
renamed EYE001), were conducted by Eyetech Pharma-
ceuticals, Inc., for the treatment of wet age-related macular 
degeneration and diabetic macular retinopathy (Eyetech 
Study group 2002; Eyetech Study group 2003). In col-
laboration with Pﬁ  zer and following approval by the Food 
and Drug Administration (FDA), the Pegaptanib sodium 
is now commercially available under the label Macugen® 
(www.macugen.com). In view of the breakthrough of 
Macugen in therapeutic applications, it seems certain that 
aptamer-based drugs are becoming a novel alternative to 
conventional drugs in the pharmacological ﬁ  eld, both in 
diagnostic uses and as therapeutics.
In fact, improvements on the aptamer pharmacokinetics 
made it possible to deposit aptamers in desired tissues under 
the control of a drug delivery system for a long-term inhibi-
tion of VEGF-induced neovascularization. Pegaptanib was 
encapsulated in poly (lactic-co-glycolic) acid (PLGA) micro-
spheres in order to gradually release the aptamer formulation. 
The drug was liberated for about 20 days at an average rate 
of 2 mg/day (Carrasquillo et al 2003). This delivery form 
represents an attractive alternative to intravitreal injection 
for AMD treatment.
Pegaptanib as a therapeutic agent
VEGF exterts several physiological and pathological func-
tions such as an increase of vascular permeability causing a 
ﬂ  uid leakage in wet AMD. As mentioned above, Pegaptanib 
selectively interacts with the heparin-binding site of the 
extracellular VEGF165 isoform and prevents VEGF165 from 
stimulating its receptor on the surface of the endothelial 
cell, thus blocking initiation of the intracellular cascade 
and consequently inhibiting vascular permeability and 
retina neovascularization (Figure 2) (Ruckman et al 1998; 
Eyetech Study Group 2002; Waheed and Miller 2004; Lee 
et al 2005).
Pegaptanib sodium is completely different from other 
drugs as the ﬁ  rst RNA drug approved by FDA and the 
ﬁ  rst anti-angiogenic agent for AMD treatment (Doggrell 
2005). In preclinical trials by using the Miles assay (Miles 
and Miles 1952; Senger et al 1986), ﬂ  uid leakage caused 
by administration of VEFG was completely inhibited by 
the addition of 100 nM of Pegaptanib. Treatment with 
Pegaptanib promoted the inhibition of 65% of VEGF-
dependent angiogenesis in animal models for corneal 
angiogenesis (Eyetech Study Group 2002). In another 
model for retinopathy of prematurity a reduction of 80% 
of retinal neovascularization was observed in the presence 
of the aptamer formulation. The phase IA clinical trial 
(a multi-center, open-label, dose-escalation study) began 
in 1998 and evaluated the effect of the drug on 15 patients 
with subfoveal choroidal neovascularization secondary to 
wet AMD. This test did not reveal any signiﬁ  cant safety 
issues related to intraocular administration of Pegaptanib 
which could be used safely up to 3 mg/eye (Eyetech Study 
Group 2002). In phase II trials (multiple-dose safety 
study), 21 patients were treated with three different doses 
(0.3, 1 and 3 mg) of the aptamer, and most of the patients 
(80%) stabilized or improved their vision after 3 months 
of Pegaptanib treatment (Eyetech Study Group 2003). 
Although all doses were well tolerated and produced 
pharmacological effects when compared to sham injection 
(p < 0.0001 for 0.3 mg, p < 0.0001 for 1 mg, p = 0.03 for 
3 mg), dose levels over 3 mg did not result in additional 
beneﬁ  ts. While the clinical trials demonstrated safety of 
Pegaptanib in all tested dosages, some undesirable side 
effects were reported which most medicines reveal. In 
phase III, most of the undesirable effects were attributed 
to injection procedures.
Following intravitreous Pegaptanib injection a mild 
increase of intraocular pressure was observed (Hariprasad 
et al 2006). Consequently, the FDA recommends tonometry 
within 30 minutes following injection and biomicroscopy 
between two and seven days subsequent to the injection. 
Other undesired adverse effects, which may occur, include 
endophthalmitis (1.3%), retinal detachment (0.6%), cataracts 
and possible allergic reactions (Steffensmeier et al 2007). 
Another obstacle for aptamer-treatment is the cost of 
Macugen being higher than that of traditional therapies 
(Zhou and Wang 2006; Smiddy 2007). However, although 
the cost of treatment with aptamers is elevated, the success 
of Macugen in effectively treating AMD opens precedents to 
start more clinical trials for new applications in other ocular 
diseases, such as diabetic macular edema (DME).
DME is caused by changes in retinal microvasculature 
and is subdivided in two variants, focal and diffuse. 
The focal variant is characterized by focal leakage of 
microaneurysms with lipoprotein accumulation. The diffuse 
variant causes diffuse leakage from retinal vessels often 
accompanied by cystoid macular changes (reviewed by 
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A phase II randomized double-masked trial was car-
ried out to evaluate the safety and efﬁ  cacy of Pegaptanib 
in the treatment of DME (Cunningham et al 2005). Three 
aptamer doses were tested (0.3, 1 and 3 mg) which were well 
accepted. The patients treated with Pegaptanib showed incre-
ments in visual acuity outcomes and additional therapies 
such as photocoagulation were necessary at a less degree 
than compared to patients which had not been treated with 
the aptamer. Although some problems related with the 
use of Pegaptanib had been reported, more than 50,000 
patients were already treated with this aptamer therapy with 
a notable clinical beneﬁ  ts to a wide range of patients with 
neovascular AMD.
Moreover, since the aptamer formulation resulted in a 
reduction of 76% of rhabdomyosarcoma tumor volume, 
further therapeutic applications for Pegaptanib are foreseen 
for diseases related to pathological VEGF165-induced 
neovascularization. Dahr et al (2007) published the results 
of a recent study on Pegaptanib use in 5 patients with 
von Hippel-Lindau (VHL) disease. The patients were 
intravitreously injected every 6 weeks with 3 mg doses. The 
whole treatment contained at least 6 injections. However, 
no signiﬁ  cant reduction in tumor growth was observed, 
although decrease of exudates indicated decrease in vascular 
permeability. The ineffective treatment with Pegaptanib 
in this case is probably due to the fact that missing 
neoangiogenesis is not sufﬁ  cient for tumor growth blockade 
in already vessel-rich environments (Blouw et al 2007). 
However, aptamer-induced inhibition of neoangiogenesis 
certainly will be promising for combating tumor growth in 
other tissue environments.
To prove the efﬁ  cacy and safety of Pegaptanib, Ng et al 
(2006) recently show as an unpublished data from VISION 
(VEGF Inhibition Study in Ocular Neovascularization) 
that patients having been treated with 0.3 mg Pegaptanib   
achieved a 45% relative beneﬁ  t in mean change in vision at 
the end of two years compared with those having received 
usual care. In addition to these results, the dosage recom-
mendation could be reviewed to deﬁ  ne the lowest effective 
dose and the longest treatment interval.
Conclusions
The demand for novel therapeutic agents acting on disease-
causing or related protein functions has turned the SELEX 
technique into a promising approach for drug discovery, tak-
ing into account that aptamers can be evolved against almost 
every target. The concept of using aptamers as therapeutic 
agents is now 17 years old and notable progress has been 
made in turning this concept into a clinical reality. In this 
context, Pegaptanib, as the most important clinical aptamer,   
is the ﬁ  rst approved oligonucleotide-based pharmacotherapy 
for the treatment of age related degeneration.
The development of Pegaptanib was based on considerable 
technical achievements produced in both academic science 
and industry. However, due to the instability of RNA 
and DNA in biological systems, early identiﬁ  ed aptamers 
were not appropriate drug candidates. After significant 
improvements regarding oligonucleotide modiﬁ  cations many 
of the stability and pharmacokinetics-related limitations were 
overcome and stabilized aptamers became available with high 
prolonged systemic exposure and notable biodistribution within 
tissues. Chemical modiﬁ  cations of oligonucleotides continue 
to be developed for further optimization of aptamer efﬁ  cacy 
and be tested in vitro and in animal models prior to clinical 
validation. Thus, it seems certain that nucleic acid based drugs 
will soon become, a standard feature of the pharmacological 
landscape, both as diagnostics and as therapeutics.
Funding
H.U. is grateful for grant support by Fundação de Amparo à 
Pesquisa do Estado de São Paulo (FAPESP) and Conselho 
Nacional de Desenvolvimento Cientíﬁ  co e Tecnológico 
(CNPq); C.A.T. and A.H.M. are supported by fellowships 
from FAPESP. J.M.A. is supported by fellowship from Coor-
denação de Aperfeiçoamento de Pessoal de Nível Superior 
(CAPES), Brazil.
Note
Considering the quantity of original research articles and 
reviews available on this topic, we may have not cited all 
important contributions to the development of anti-VEGF 
aptamers into therapeutics.
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